Skip to main content

Chronic Burping and Belching



Belching is a physiological event that allows venting of swallowed gastric air. Excessive belching is a common presentation to gastroenterology clinics and could be isolated complains or associated with other gastrointestinal problems.

Purpose of this Review

It is to describe the presentation, diagnosis, and treatment of belching disorders

Recent Findings

These demonstrate that learned abnormal behaviors in response to unpleasant feeling in the abdomen are the driving causes for excessive belching and addressing these behaviors by speech pathology and cognitive behavior therapy considered as the keystone in its management


The gold standard in the diagnosis of belching is impedance monitoring by which belching is classified into supragastric belching and gastric belching.


Belching or eructation is defined as a sudden escape of a gaseous bolus from the esophagus to pharynx which could be audible or silent [1]. It is considered as a physiologic event which normally happens up to 30 times a day [2]. However, excessive belching can become reason for consultation when it is repetitive and interferes with day-to-day activity and affects the quality of life of patients [3]. There is no systematic study on epidemiology of belching, but in one study, up to 50% of patients with dyspepsia also complained of excessive belching. In this group, belching was interfering with their social life in 20% [4]. It is estimated that approximately 3.4% of patients referred to tertiary hospitals for upper gastrointestinal problem suffer from supragastric belching [5].


There are two different types of belching: supragastric belching and gastric belching. Supragastric belching is considered as an unintentional reaction to unpleasant feeling in the abdomen and/or retrosternal region which does not happen during sleep [6], speech [1, 7], or during patient’s distraction [7]. There are two primary mechanisms for supragastric belching which consist of air suction and air injection. In air suction, patients subconsciously contract the skeletal muscle part in the diaphragm which results in negative pressure in the esophagus. In this situation, when the upper esophageal sphincter relaxes, the pressure difference between pharynx and atmosphere results in the rapid inflow of air into the esophagus. Subsequently, the air in the esophagus forces out of the esophagus again during straining which is perceived as belching [1, 8••, 9]. In the air injection mechanism of supragastric belching, voluntary contraction of the base of the tongue results in elevated pharyngeal pressure and unchanged esophageal pressure which results in pushing of air from the pharynx to the esophagus. Again, air is expelled from the esophagus during straining. In both mechanisms, air does not enter the stomach; the reason it is called supragastric belching. Although supragastric belching is initially considered as an voluntary response of patients to unpleasant feeling in the upper abdomen or chest, it is through activation of voluntary muscle and over time becomes a firmly established habit in patients. There is not enough evidence to support the cause and effect relation between supragastric belching and psychological disorders such as anxiety and depression, but these conditions are associated with it. Also, supragastric belching results in a significant reduction in the quality of life of patients [3, 10].

Gastric belching occurs with impetuous release of air from the stomach through transient relaxation of the lower esophageal sphincter (TLESR); this is a gastric venting mechanism that prevents excessive abdominal distention by swallowed air [11,12,13]. It is a physiological mechanism and triggers by gastric extension which happens in average of 30 times in 24 h, more frequently after consumption of carbonated beverages [11]. Gamma-aminobutyric acid, metabotropic glutamate receptors, cannabinoid receptor 1, nitric oxide, and cholecystokinin are neurotransmitters that impact the amount of TLESRs [14,15,16,17].

Belching in patients with gastroesophageal reflux disease (GERD)

Proton-pump inhibitors (PPIs) which are commonly used in treatment of GERD symptoms are considered effective in reducing the number of belches as well [19,20,21,22]. Perhaps this can be explained by the notion that PPIs reduce the unpleasant abdominal or retrosternal sensation that triggers the behavior and leads to supragastric belching.

The study with ambulatory impedance monitoring by Hemmink et al. showed that about 50% of patients with GERD also presented with supragastric belches. The mechanism of reflux and its temporal association with supragastric belching revealed two association patterns; 18% of the supragastric belches occurred very soon after acid reflux and responded well to proton-pump inhibitors which treat reflux symptoms. However, in 30% of patients, supragastric belching happened prior to acid reflux. It is believed that supragastric belching in this group triggered the reflux, and these patients did therefore not respond to proton-pump inhibitors [18].

Belching in patient with functional dyspepsia

Belching is a common complaint in patients who are suffering from other functional upper gastrointestinal diseases besides GERD. Conchillo et al. found that patients with functional dyspepsia have more frequent gas reflux symptoms. However, the author does not specifically assess supragastric belching in this small study [21].

Belching and rumination syndrome

Rumination syndrome is defined as a recurrent unintentional regurgitation of recently consumed food. The mechanism of rumination syndrome is the habitual contracture of voluntary abdominal muscle which result in increasing the intragastric pressure which drives gastric contents into the esophagus and higher [23, 24••].

A study by Kessing et al. revealed that supragastric belching could induce rumination in a subgroup of patients with rumination syndrome. In this group, supragastric belching triggers the sharp increase in the intragastric pressure which forces out the gastric content within the esophagus and results in regurgitation of food [25, 26•].


The term aerophagia is sometimes confused with supragastric belching. In aerophagia excessive air is swallowed and transported to the intestines and colon. Patients complain of bloating and flatulence. There are three major differences between aerophagia and supragastric belching. Firstly, in aerophagia the air is swallowed and transported distally by peristalsis, while in supragastric belching, this is done by air suction or pharyngeal air pushing [8••, 27, 28]. Secondly, in aerophagia the air is mainly found in the intestines and colon, while in supragastric belching, the air stays proximal of the stomach [18]. Thirdly, in aerophagia patients complain of bloating, abdominal distention, and flatulence, while in supragastric belching, the primary symptom is belching [29].

Clinical evaluation and diagnostic approach

The first step in the clinical evaluation of the patient with excessive belching is a comprehensive history and physical examination. This helps to ensure that red flags for organic disorders, such as weight loss and dysphagia, do not exist and also to better understand the clinical pattern including the frequency and timing of belching [30].

Impedance monitoring is the gold standard in the diagnosis of belching and aerophagia and helps to identify the underlying cause of belching and to differentiate supragastric belching from gastric belching [29, 31]. Impedance allows the presence and movement patterns of air in the esophagus. It helps to study belching by providing objective evidence of supragastric belching events. Intraluminal esophageal impedance monitoring is also helpful in the detection of esophageal transit of fluid boluses and gastroesophageal reflux. Gastric belching is characterized by an increase in impedance level starting in the distal channel and progressing to the most proximal channel (Fig. 1). Criteria for diagnosis of supragastric belching is a rapid antegrade movement of gas (impedance of 1000 Ω), followed by retrograde expulsion back to the baseline impedance level (Fig. 2) [8••]. Up to 13 events of supragastric belching in 24 h have been demonstrated to be physiologic in asymptomatic patients which considered as an upper limit of normal; we therefore assume this can go unnoticed in healthy subjects as well. Patients with symptomatic supragastric belching have average of 101 events in 24 h (ranging from 7 to 510) which is much higher even when compared to the patients with gastric belching [5]. In another study, on 90-min impedance monitoring, the median number of belching events captured for patients with gastric belching was 1, compared with 36 for those with supragastric belching [9]. This helps experienced gastroenterologist to spot the diagnosis of supragastric belching on a quick overview of impedance monitoring based on characteristic day-time density of symptom markers and impedance “spikes” of intraesophageal air movement, notably absent during sleep [6].

Fig. 1
figure 1

Gastric belching during liquid reflux episode. In this figure, impedance monitoring shows a decrease in impedance starting distally and moving in proximal direction (blue arrow) and an increase in impedance level starts during the liquid reflux episode spreading in proximal direction

Fig. 2
figure 2

Supragastric belching. In this figure, the impedance monitoring shows an increase of impedance level form the proximal channel to the most distal impedance channel

High-resolution manometry (HRM) is not commonly recommended in diagnosis of supragastric belching, but if combined with impedance, monitoring helps to differentiate between supragastric belching, gastric belching, and rumination syndrome. It also allows to distinguish the underlying manometric technique, air suction, or pharyngeal air pushing, although it is not clear if this helps treatment [30].

Treatment of belching

The keystone for treating patients with supragastric belching and gastric belching is a comprehensive clarification of the etiology of these symptoms which makes the patient aware that this is a behavioral disorder. It is often challenging for the patient to accept that there is no pathological explanation for their disease [1]. The most described effective treatment for supragastric belching is behavioral modification known as psychoeducation [32].

Speech therapy is the most described treatment in supragastric belching. A report by Ten Cate et al. on 48 patients revealed 83% of patients with supragastric belching responded well to behavioral modification with a significant reduction of the total median visual analogue scale (VAS) from 406 to 125. In this method, an experienced speech pathologist provided care in ten sessions with average of 60 min for the first three sessions followed by 30 min of training for the remaining sessions. The treatment gives the patients insight into the underlying behavioral problem related to excessive swallowing of air and strategies to tackle it. These strategies include changing the unconscious act of breathing and swallowing to more conscious and purposeful movement by retraining of respiratory muscle with tight glottal/laryngeal contraction and mouth closure, paying more attention to the pathophysiology of supragastric belching and controlling of air influx during breathing. Abdominal breathing was also beneficial in the reduction of belching symptoms. In severe cases, patients were encouraged to retrain their breathing, while they put their finger between their mouth and breath by open mouth [33]. Katzka also described that supragastric belching is not possible when asking the patient to use a pencil between the teeth [34•]. Speech therapy also improves the coordination between the lingual, laryngeal, and cricopharyngeal muscles by relaxation of the maxilla, laryngeal manipulation, and Boone’s voice facilitating’s maneuver to prevent any unusual movement of the tongue, larynx, and upper esophageal sphincter which cause supragastric belching. The response rate was assessed by VAS which considers the effect of belching on both personal and social life of affected patients and also the degree of patients’ control on their symptoms. This technique should be practiced on a daily basis until the patients picks up the new habits. The previous study by Hemmink et al. also confirmed that speech therapy is helpful in patients with supragastric belching. In this study, 6 out of 11 patients had more than 30% improvement in their VAS score, and the rest of them showed some degree of improvement [35]. Speech therapy has been tried differently in different studies. Riehl et al. examined a two-session protocol, based on their pilot study of a psychologist delivering psychoeducation and instructions on relaxed open-mouth breathing. They achieved 75% reduction in symptom at 3 months [32]. Also, one education session on sustained glottal opening showed complete improvement in supragastric belching at 1 month in 80% of patients as demonstrated by Katzka [34•].

Cognitive behavioral therapy (CBT) was also effective in the treatment of supragastric belching as shown in the study by Glasinovic et al. In this interventional study, the severity of symptoms was assessed pre- and posttreatment. The intervention involved five CBT sessions which have three components: a cognitive part, a behavioral component, and an assessment of treatment and outcome. In the first session, patients were separately assessed by gastroenterologist and psychologist, and the contributing psychosocial factors were identified. In the following sessions, the treatment was initiated with a focus on assisting the patient how to recognize the etiology of the disease, triggering factors and explanation of how treatment could improve their symptoms. The critical component of CBT was to recognize the warning signs which most patients described as abnormal tension or uncomfortable pressure-like feeling in the retrosternal area just before the supragastric belching starts. Following this warning sign, they were encouraged to practice awareness training technique to stop belching with diaphragmatic breathing, mouth opening, and tongue positioning. The patients were assessed based on MII-pH pre- and posttreatment at 8 weeks. Cognitive behavioral therapy resulted in more than 50% reduction in belching symptoms in more than 50% of patients. It was also effective in decreasing the esophageal acid exposure time in the patients with elevated acid exposure time at baseline and declining of mean VAS score from 260 to 140. CBT also decreased the frequency of supragastric belching and associated esophageal acid reflux, but it was not effective in reducing the frequency of gastric belching [36].

A randomized double-blinded placebo-controlled study was performed by Pauwels et al. on the effect of baclofen on 25 patients with supragastric belching and rumination syndrome who did not respond to PPIs [37]. Baclofen is a gamma-aminobutyric acid (GABA) receptor agonist which is commonly used for muscle spasticity and also inhibits TLESRs [38,39,40,41,42] .Regurgitation was the main symptom in 16 patients; belching was predominant in 5. The patients were commenced on 10-mg baclofen, three times a day for 2 weeks, and were then assessed by high-resolution manometry. This study showed that baclofen significantly decreases the number of rumination episodes and the ratio of rumination to straining. However, it was not effective in the treatment of supragastric belching. In patients treated with baclofen, the pressure of postprandial lower esophageal sphincter was considerably higher than the placebo group which resulted in the reduction of the number of rumination symptoms. However, the frequency of postprandial TLESRs was considerably less than the placebo group [37]. Another study on a small number of patients revealed improvement in symptoms and reduction in postprandial flow events in patients with rumination and SBG who treated with baclofen [43].

In a study by Oor et al., upper gastrointestinal endoscopy, esophageal manometry, and 24-h pH impedance were used to compare the effectiveness of different methods of partial fundoplication in controlling reflux symptoms and also post-operation gastric belching and SGB. Two partial fundoplication methods include the laparoscopic 270° posterior or Toupet fundoplication and 180° anterior fundoplication. This study showed that Toupet fundoplication and anterior fundoplication controlled reflux symptoms equally and resulted in a similar reduction in the number of belching and supragastric belching [44].


Belching is a common physiological symptom in general population which can happen isolated or associated with other gastrointestinal complains such as GERD, rumination syndrome, or functional dyspepsia. Impedance monitoring helped to better understand the pathophysiology of belching and to divide belching to gastric or supragastric belching based on its mechanism.

Psychoeducation is considered as the most effective strategy for treatment of supragastric belching and consists of speech pathology and cognitive behavioral therapy. Baclofen effectiveness in symptoms management varied in different studies, and it is recommended to use baclofen only if other treatment options failed.



Supragastric belching


Gastric belching


Upper esophageal sphincter


Lower esophageal sphincter


Transient lower esophageal sphincter relaxation


Gastroesophageal reflux disease


Proton-pump inhibitors


High-resolution manometry


High-resolution manometry plus impedance monitoring


Visual analogue scale


Cognitive behavioral therapy


Acid exposure time


Gamma-aminobutyric acid


Toupet fundoplication


180-degree anterior fundoplication

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Kessing BF, Bredenoord AJ, Smout AJ. The pathophysiology, diagnosis and treatment of excessive belching symptoms. Am J Gastroenterol. 2014;109(8):1196–203 (Quiz) 204.

    PubMed  Google Scholar 

  2. Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Air swallowing, belching, and reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2006;101(8):1721–6.

    PubMed  Google Scholar 

  3. Bredenoord AJ, Smout AJ. Impaired health-related quality of life in patients with excessive supragastric belching. Eur J Gastroenterol Hepatol. 2010;22(12):1420–3.

    PubMed  Google Scholar 

  4. Piessevaux H, De Winter B, Louis E, Muls V, De Looze D, Pelckmans P, et al. Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol Motil. 2009;21(4):378–88.

    CAS  PubMed  Google Scholar 

  5. Koukias N, Woodland P, Yazaki E, Sifrim D. Supragastric belching: prevalence and association with Gastroesophageal reflux disease and esophageal Hypomotility. J Neurogastroenterol Motil. 2015;21(3):398–403.

    PubMed  PubMed Central  Google Scholar 

  6. Karamanolis G, Triantafyllou K, Tsiamoulos Z, Polymeros D, Kalli T, Misailidis N, et al. Effect of sleep on excessive belching: a 24-hour impedance-pH study. J Clin Gastroenterol. 2010;44(5):332–4.

    PubMed  Google Scholar 

  7. Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Psychological factors affect the frequency of belching in patients with aerophagia. Am J Gastroenterol. 2006;101(12):2777–81.

    PubMed  Google Scholar 

  8. •• Bredenoord AJ, Weusten BL, Sifrim D, Timmer R, Smout AJ. Aerophagia, gastric, and supragastric belching: a study using intraluminal electrical impedance monitoring. Gut. 2004;53(11):1561–5 First description of supragastric belching.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Kessing BF, Bredenoord AJ, Smout AJ. Mechanisms of gastric and supragastric belching: a study using concurrent high-resolution manometry and impedance monitoring. Neurogastroenterol Motil. 2012;24(12):e573–9.

    CAS  PubMed  Google Scholar 

  10. Chitkara DK, Bredenoord AJ, Rucker MJ, Talley NJ. Aerophagia in adults: a comparison with functional dyspepsia. Aliment Pharmacol Ther. 2005;22(9):855–8.

    CAS  PubMed  Google Scholar 

  11. Wyman JB, Dent J, Heddle R, Dodds WJ, Toouli J, Downton J. Control of belching by the lower oesophageal sphincter. Gut. 1990;31(6):639–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Kessing BF, Conchillo JM, Bredenoord AJ, Smout AJ, Masclee AA. Review article: the clinical relevance of transient lower oesophageal sphincter relaxations in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011;33(6):650–61.

    CAS  PubMed  Google Scholar 

  13. Dent J, Holloway RH, Toouli J, Dodds WJ. Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux. Gut. 1988;29(8):1020–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology. 2000;118(1):7–13.

    CAS  PubMed  Google Scholar 

  15. Frisby CL, Mattsson JP, Jensen JM, Lehmann A, Dent J, Blackshaw LA. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology. 2005;129(3):995–1004.

    CAS  PubMed  Google Scholar 

  16. Partosoedarso ER, Abrahams TP, Scullion RT, Moerschbaecher JM, Hornby PJ. Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol. 2003;550(Pt 1):149–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Hirsch DP, Holloway RH, Tytgat GN, Boeckxstaens GE. Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology. 1998;115(6):1374–80.

    CAS  PubMed  Google Scholar 

  18. Hemmink GJ, Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Supragastric belching in patients with reflux symptoms. Am J Gastroenterol. 2009;104(8):1992–7.

    PubMed  Google Scholar 

  19. Kahrilas PJ, Miner P, Johanson J, Mao L, Jokubaitis L, Sloan S. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci. 2005;50(11):2009–18.

    CAS  PubMed  Google Scholar 

  20. Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97(6):1332–9.

    CAS  PubMed  Google Scholar 

  21. Gerson LB, Kahrilas PJ, Fass R. Insights into gastroesophageal reflux disease-associated dyspeptic symptoms. Clin Gastroenterol Hepatol. 2011;9(10):824–33.

    PubMed  Google Scholar 

  22. Kriengkirakul C, Patcharatrakul T, Gonlachanvit S. The therapeutic and diagnostic value of 2-week high dose proton pump inhibitor treatment in overlapping non-erosive gastroesophageal reflux disease and functional dyspepsia patients. J Neurogastroenterol Motil. 2012;18(2):174–80.

    PubMed  PubMed Central  Google Scholar 

  23. Kessing BF, Govaert F, Masclee AA, Conchillo JM. Impedance measurements and high-resolution manometry help to better define rumination episodes. Scand J Gastroenterol. 2011;46(11):1310–5.

    PubMed  Google Scholar 

  24. •• Rommel N, Tack J, Arts J, Caenepeel P, Bisschops R, Sifrim D. Rumination or belching-regurgitation? Differential diagnosis using oesophageal impedance-manometry. Neurogastroenterol Motil. 2010;22(4):e97–104 Clear explanation of difference between rumiantion and belching.

    CAS  PubMed  Google Scholar 

  25. Tucker E, Knowles K, Wright J, Fox MR. Rumination variations: aetiology and classification of abnormal behavioural responses to digestive symptoms based on high-resolution manometry studies. Aliment Pharmacol Ther. 2013;37(2):263–74.

    CAS  PubMed  Google Scholar 

  26. • Kessing BF, Bredenoord AJ, Smout AJ. Objective manometric criteria for the rumination syndrome. Am J Gastroenterol. 2014;109(1):52–9 Introduces 3 different subtypes of rumination.

    PubMed  Google Scholar 

  27. Bredenoord AJ. Excessive belching and aerophagia: two different disorders. Dis Esophagus. 2010;23(4):347–52.

    PubMed  Google Scholar 

  28. Bredenoord AJ, Weusten BL, Timmer R, Akkermans LM, Smout AJ. Relationships between air swallowing, intragastric air, belching and gastro-oesophageal reflux. Neurogastroenterol Motil. 2005;17(3):341–7.

    CAS  PubMed  Google Scholar 

  29. Hemmink GJ, Weusten BL, Bredenoord AJ, Timmer R, Smout AJ. Aerophagia: excessive air swallowing demonstrated by esophageal impedance monitoring. Clin Gastroenterol Hepatol. 2009;7(10):1127–9.

    PubMed  Google Scholar 

  30. Saleh CM, Bredenoord AJ. Utilization of esophageal function testing for the diagnosis of the rumination syndrome and belching disorders. Gastrointest Endosc Clin N Am. 2014;24(4):633–42.

    PubMed  Google Scholar 

  31. Bredenoord AJ, Smout AJ. Physiologic and pathologic belching. Clin Gastroenterol Hepatol. 2007;5(7):772–5.

    PubMed  Google Scholar 

  32. Riehl ME, Kinsinger S, Kahrilas PJ, Pandolfino JE, Keefer L. Role of a health psychologist in the management of functional esophageal complaints. Dis Esophagus. 2015;28(5):428–36.

    CAS  PubMed  Google Scholar 

  33. Ten Cate L, Herregods TVK, Dejonckere PH, Hemmink GJM, Smout A, Bredenoord AJ. Speech therapy as treatment for Supragastric belching. Dysphagia. 2018;33(5):707–15.

    PubMed  Google Scholar 

  34. •• Katzka DA. Simple office-based behavioral approach to patients with chronic belching. Dis Esophagus. 2013;26(6):570–3 Provides further insights into supragastric belching.

    CAS  PubMed  Google Scholar 

  35. Hemmink GJ, Ten Cate L, Bredenoord AJ, Timmer R, Weusten BL, Smout AJ. Speech therapy in patients with excessive supragastric belching--a pilot study. Neurogastroenterol Motil. 2010;22(1):24–8 e2-3.

    CAS  PubMed  Google Scholar 

  36. Glasinovic E, Wynter E, Arguero J, Ooi J, Nakagawa K, Yazaki E, et al. Treatment of supragastric belching with cognitive behavioral therapy improves quality of life and reduces acid gastroesophageal reflux. Am J Gastroenterol. 2018;113(4):539–47.

    CAS  PubMed  Google Scholar 

  37. Pauwels A, Broers C, Van Houtte B, Rommel N, Vanuytsel T, Tack J. A randomized double-blind, placebo-controlled, cross-over study using baclofen in the treatment of rumination syndrome. Am J Gastroenterol. 2018;113(1):97–104.

    CAS  PubMed  Google Scholar 

  38. Hasler WL. Baclofen effects on esophageal function: a possible therapy for GERD? Gastroenterology. 2002;123(5):1736–7.

    PubMed  Google Scholar 

  39. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut. 2003;52(10):1397–402.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. van Herwaarden MA, Samsom M, Rydholm H, Smout AJ. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther. 2002;16(9):1655–62.

    PubMed  Google Scholar 

  41. Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther. 2003;17(2):243–51.

    CAS  PubMed  Google Scholar 

  42. Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut. 2002;50(1):19–24.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Blondeau K, Boecxstaens V, Rommel N, Farre R, Depeyper S, Holvoet L, et al. Baclofen improves symptoms and reduces postprandial flow events in patients with rumination and supragastric belching. Clin Gastroenterol Hepatol. 2012;10(4):379–84.

    CAS  PubMed  Google Scholar 

  44. Oor JE, Broeders JA, Roks DJ, Oors JM, Weusten BL, Bredenoord AJ, et al. Reflux and belching after laparoscopic 270 degree posterior versus 180 degree anterior partial fundoplication. J Gastrointest Surg. 2018;22(11):1852–60.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to A. J. Bredenoord.

Ethics declarations

Conflict of Interest

AZ does not have anything to disclose. AJB received research funding from Nutricia, Norgine, and Bayer and received speaker and/or consulting fees from Laborie, EsoCap, Diversatek, Medtronic, Dr. Falk Pharma, Calypso Biotech, Thelial, Robarts, Reckett Benkiser, Regeneron, Celgene, Bayer, Norgine, AstraZeneca, Almirall and Allergan.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Neurogastroenterology and GI Motiliy

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zad, M., Bredenoord, A.J. Chronic Burping and Belching. Curr Treat Options Gastro 18, 33–42 (2020).

Download citation

  • Published:

  • Issue Date:

  • DOI:


  • Supragastric belching
  • Speech therapy
  • Cognitive behavioral therapy
  • Baclofen